Celldex Therapeutics Inc.’s filing revealed that its SVP AND CFO Martin Samuel Bates unloaded Company’s shares for reported $0.61 million on Jun 14 ’24. In the deal valued at $35.42 per share,17,172 shares were sold. As a result of this transaction, Martin Samuel Bates now holds 28,125 shares worth roughly $0.79 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Crowley Elizabeth sold 30,000 shares, generating $1,045,962 in total proceeds. Upon selling the shares at $34.87, the SR. VP & CPDO now owns 9,074 shares.
Before that, Crowley Elizabeth sold 15,000 shares. Celldex Therapeutics Inc. shares valued at $525,873 were divested by the SR. VP & CPDO at a price of $35.06 per share. As a result of the transaction, Crowley Elizabeth now holds 9,074 shares, worth roughly $0.26 million.
Citigroup initiated its Celldex Therapeutics Inc. [CLDX] rating to a Buy in a research note published on October 07, 2024; the price target was $70. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late September with a ‘”a Neutral”‘ rating. Wolfe Research also remained covering CLDX and has decreased its forecast on September 27, 2024 with a “Peer perform” recommendation from previously “an Outperform” rating. Stifel started covering the stock on June 18, 2024. It rated CLDX as “a Buy”.
Price Performance Review of CLDX
On Friday, Celldex Therapeutics Inc. [NASDAQ:CLDX] saw its stock fall -1.70% to $28.25. Over the last five days, the stock has lost -9.80%. Celldex Therapeutics Inc. shares have fallen nearly -28.77% since the year began. Nevertheless, the stocks have risen 17.71% over the past one year. While a 52-week high of $53.18 was reached on 03/04/24, a 52-week low of $22.11 was recorded on 10/18/24. SMA at 50 days reached $36.16, while 200 days put it at $38.32.
Levels Of Support And Resistance For CLDX Stock
The 24-hour chart illustrates a support level at 27.87, which if violated will result in even more drops to 27.50. On the upside, there is a resistance level at 28.81. A further resistance level may holdings at 29.38. The Relative Strength Index (RSI) on the 14-day chart is 30.33, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.28, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.05%. Stochastics %K at 6.28% indicates the stock is a buying.
How much short interest is there in Celldex Therapeutics Inc.?
A steep rise in short interest was recorded in Celldex Therapeutics Inc. stocks on 2024-09-30, dropping by -0.27 million shares to a total of 8.31 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-30 was 8.57 million shares. There was a decline of -3.19%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on June 11, 2024 when Wolfe Research began covering the stock and recommended ‘”an Outperform”‘ rating along with a $51 price target.
